{
    "article_link": "https://www.frontiersin.org/articles/10.3389/fonc.2023.1186858/full",
    "data": [
        {
            "id": "data_1",
            "omics": "Transcriptomics",
            "link": "https://xenabrowser.net/datapages/",
            "format": "txt",
            "source": "The Cancer Genome Atlas (TCGA)",
            "public_id": "TCGA-BRCA"
        },
        {
            "id": "data_2",
            "omics": "Genomics",
            "link": "https://xenabrowser.net/datapages/",
            "format": "txt",
            "source": "The Cancer Genome Atlas (TCGA)",
            "public_id": "TCGA-BRCA"
        },
        {
            "id": "data_3",
            "omics": "Epigenomics",
            "link": "https://xenabrowser.net/datapages/",
            "format": "txt",
            "source": "The Cancer Genome Atlas (TCGA)",
            "public_id": "TCGA-BRCA"
        },
        {
            "id": "data_4",
            "omics": "Transcriptomics",
            "link": "http://www.ncbi.nlm.nih.gov/geo/",
            "format": "txt",
            "source": "Gene Expression Omnibus (GEO)",
            "public_id": "GSE7390"
        },
        {
            "id": "data_5",
            "omics": "Transcriptomics",
            "link": "http://www.ncbi.nlm.nih.gov/geo/",
            "format": "txt",
            "source": "Gene Expression Omnibus (GEO)",
            "public_id": "GSE20685"
        },
        {
            "id": "data_6",
            "omics": "Transcriptomics",
            "link": "http://www.ncbi.nlm.nih.gov/geo/",
            "format": "txt",
            "source": "Gene Expression Omnibus (GEO)",
            "public_id": "GSE103091"
        },
        {
            "id": "data_7",
            "omics": "Single-cell Transcriptomics",
            "link": "http://www.ncbi.nlm.nih.gov/geo/",
            "format": "txt",
            "source": "Gene Expression Omnibus (GEO)",
            "public_id": "GSE176078"
        },
        {
            "id": "data_8",
            "omics": "Pharmacogenomics",
            "link": null,
            "format": null,
            "source": "The Genomics of Drug Sensitivity in Cancer (GDSC)",
            "public_id": null
        }
    ],
    "analyses": [
        {
            "id": "analysis_1",
            "analysis_name": "Multi-omics gene screening",
            "analysis_data": [
                "data_1",
                "data_2",
                "data_3"
            ],
            "label": null
        },
        {
            "id": "analysis_2",
            "analysis_name": "Differential analysis",
            "analysis_data": [
                "data_1",
                "data_3"
            ],
            "label": {
                "CNV_status": [
                    "high",
                    "low"
                ]
            }
        },
        {
            "id": "analysis_3",
            "analysis_name": "Risk score (RS) signature construction",
            "analysis_data": [
                "analysis_1"
            ],
            "label": null
        },
        {
            "id": "analysis_4",
            "analysis_name": "Prognostic validation",
            "analysis_data": [
                "data_4",
                "data_5",
                "data_6"
            ],
            "label": null
        },
        {
            "id": "analysis_5",
            "analysis_name": "Stratification analysis by disease stages",
            "analysis_data": [
                "analysis_3"
            ],
            "label": {
                "stage": [
                    "I/II",
                    "III/IV"
                ]
            }
        },
        {
            "id": "analysis_6",
            "analysis_name": "Stratification analysis by molecular subtypes",
            "analysis_data": [
                "analysis_3"
            ],
            "label": {
                "subtypes": [
                    "ER-negative",
                    "ER-positive",
                    "PR-negative",
                    "PR-positive",
                    "HER2-negative",
                    "HER2-positive"
                ]
            }
        },
        {
            "id": "analysis_7",
            "analysis_name": "Single-cell cluster analysis",
            "analysis_data": [
                "data_7"
            ],
            "label": {
                "RS": [
                    "high",
                    "low"
                ]
            }
        },
        {
            "id": "analysis_8",
            "analysis_name": "Immune checkpoint analysis",
            "analysis_data": [
                "data_1",
                "data_6"
            ],
            "label": {
                "RS": [
                    "high",
                    "low"
                ]
            }
        },
        {
            "id": "analysis_9",
            "analysis_name": "Drug sensitivity analysis",
            "analysis_data": [
                "data_8"
            ],
            "label": {
                "RS": [
                    "high",
                    "low"
                ]
            }
        }
    ],
    "results": [
        {
            "analysis_id": "analysis_3",
            "metrics": "AUC",
            "value": "0.738 (3 years), 0.701 (5 years)",
            "features": [
                "C15orf52",
                "C1orf228",
                "CEL",
                "FUZ",
                "PAK6",
                "SIRPG"
            ]
        },
        {
            "analysis_id": "analysis_4",
            "metrics": "AUC",
            "value": "0.675 (3 years, validation set 1), 0.657 (5 years, validation set 1), 0.690 (3 years, validation set 2), 0.609 (5 years, validation set 2)",
            "features": [
                "C15orf52",
                "C1orf228",
                "CEL",
                "FUZ",
                "PAK6",
                "SIRPG"
            ]
        },
        {
            "analysis_id": "analysis_5",
            "metrics": "AUC",
            "value": "0.766 (3 years, stages I/II), 0.712 (5 years, stages I/II), 0.689 (3 years, stages III/IV), 0.708 (5 years, stages III/IV)",
            "features": [
                "C15orf52",
                "C1orf228",
                "CEL",
                "FUZ",
                "PAK6",
                "SIRPG"
            ]
        },
        {
            "analysis_id": "analysis_6",
            "metrics": "AUC",
            "value": "0.675 (3 years, ER-negative), 0.751 (3 years, ER-positive), 0.714 (3 years, PR-negative), 0.708 (3 years, PR-positive), 0.711 (3 years, HER2-negative), 0.795 (3 years, HER2-positive)",
            "features": [
                "C15orf52",
                "C1orf228",
                "CEL",
                "FUZ",
                "PAK6",
                "SIRPG"
            ]
        },
        {
            "analysis_id": "analysis_7",
            "metrics": null,
            "value": null,
            "features": [
                "MSC (mesenchymal stem cells)",
                "T cell subpopulations"
            ]
        },
        {
            "analysis_id": "analysis_8",
            "metrics": null,
            "value": null,
            "features": [
                "BTLA",
                "CD200R1",
                "CD27",
                "CD28",
                "CD40",
                "CD40LG",
                "CTLA4",
                "HLA-DRB1",
                "IL2RB",
                "LAG3",
                "PDCD1",
                "TIGIT",
                "TNFRSF14"
            ]
        },
        {
            "analysis_id": "analysis_9",
            "metrics": "IC50",
            "value": "Lower IC50 for BI2536 in high-risk subgroup",
            "features": [
                "BI2536",
                "Camptothecin",
                "Epirubicin",
                "Vinnorelbine"
            ]
        }
    ]
}